-
One-third of non-small cell lung cancer patients treated with adjuvant chemotherapy start it more than 10 weeks after surgery. Although the time interval between surgery and initiation of adjuvant chemotherapy impacts survival in colorectal and breast cancers, delaying adjuvant chemotherapy does not appear to be associated with inferior survival in non-small cell lung cancer.
-
Beta-blockers and noncardiac surgery; prenatal medication exposure and risk of autism; reasons for statin discontinuations; and FDA actions.
-
Clinically significant disparities exist in the quality of ovarian cancer care delivered and in overall survival along both racial and socioeconomic status. These effects appear to persist despite adherence to National Comprehensive Cancer Network guidelines; however, deviation in guideline adherence is common and further impacts survivorship and represents key opportunities for further investigation and study.
-
Current strategies to prevent chemotherapy-induced nausea and vomiting frequently include a 3-day course of aprepitant. In a multicenter trial from Japan, administration of a single dose of the aprepitant prodrug fosaprepitant, when used in combination with granisetron and dexamethasone, was shown to provide significant improvement when compared to placebo plus granisetron/dexamethasone. Thus, single-dose fosaprepitant may offer a more convenient and less complicated approach in the regimen to prevent nausea and vomiting.
-
-
In this study, the authors studied the prognostic value of plasma Epstein Barr virus (EBV) DNA levels at diagnosis and 6 months post-treatment in patients with advanced Hodgkin lymphoma treated on the North American Cooperative Intergroup Trial E2496.
-
A recent review of the literature evaluating methods to decrease preterm birth in twins has shown little or no benefit of bed rest, cerclage, or 17 alpha-hydroxy progesterone.
-
-
In this retrospective, cohort study, a see-and-treat protocol resulted in only a 4.5% overtreatment rate.
-
Infants of women initiating either a combined oral contraceptive, the levonorgestrel IUS, the etonogestrel implant, or a copper IUD at 42 days postpartum ingested similar volumes of breast milk and displayed similar growth.